Hjem › Follikulært lymfom › Ohio
Follikulært lymfom kliniske forsøg i Ohio
23 studier for Follikulært lymfom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
RekruttererFase 3
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07215910Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- The Ohio State University (OSU), Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Blue Ash
- Research Site, Cincinnati
- Research Site, Columbus
RekruttererFase 3
Alder 18 til 130 · Alle køn · Opdateret 21. sep. 2026 · NCT06549595Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06526793A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06091254Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07225439A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Cincinnati, Cincinnati
- OhioHealth Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
RekruttererObservationsstudie
Alder 0 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07154823Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579STimulation to Activate RespIration
- Cleveland Clinic, Cleveland
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT06832306A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022Epcoritamab and Rituximab for First-line Follicular Lymphoma
- The Ohio State University Wexner Medical Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. maj 2026 · NCT05783609The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Taylor Cancer Research Center, Maumee
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. dec. 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.